Not much info - Teva is partnering with Antisense Therapeutics to help the latter get its MS drug - ATL-1102 - (currently Phase II) to market. ATL-1102 has a similar approach as Tysabri.
This is the second story within a month of a large drugs company partnering with a smaller one (other one was BioMS and Lilly).
Probably shows that these drugs show some promise.
Ian
http://c.moreover.com/click/here.pl?j12 ... 5&w=464753
Antisense - ATL-1102
A bit more on the partnering arrangement (see news on right hand side).
Phase IIa results are expected in mid 2008.
http://www.antisense.com.au/!upload_fil ... 20Teva.pdf
Phase IIa results are expected in mid 2008.
http://www.antisense.com.au/!upload_fil ... 20Teva.pdf